Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509867 | 1.00 | SIRT3 (0.37) | SIRT3TDP1NNMTDGAT1GRM5 | |
| SCHEMBL28915362 | 0.83 | DGAT1 (0.43) | NNMTDGAT1GRM5POLBLMNA | |
| SCHEMBL9592586 | 0.82 | PKMYT1 (0.36) | NNMTGRM5POLBLMNAADORA2A | |
| SCHEMBL18779089 | 0.82 | PDPK1 (0.44) | NNMTGRM5POLBLMNAADORA2A | |
| SCHEMBL7422568 | 0.81 | HPGD (0.39) | TDP1GRM5JAK3KDM4EPKM | |
| SCHEMBL30112052 | 0.81 | HPGD (0.39) | TDP1GRM5JAK3KDM4EPKM | |
| SCHEMBL2491805 | 0.81 | SMN1; SMN2 (0.40) | GRM5POLBJAK3KDM4EADORA2B | |
| SCHEMBL29361842 | 0.81 | SMN1; SMN2 (0.40) | GRM5POLBJAK3KDM4EADORA2B | |
| SCHEMBL19754916 | 0.80 | POLB (0.50) | NNMTGRM5POLBLMNAJAK3 | |
| SCHEMBL27559460 | 0.80 | SIRT3 (0.35) | SIRT3TDP1NNMTDGAT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2685821-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | AbbVie Inc. (US) | 2014-01-22 | — | — | EP | claimed |
| US-20120238549-A1 | Nuclear Hormone Receptor Modulators | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | US | claimed |
| WO-2012125797-A1 | NUCLEAR HORMONE RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | WO | claimed |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240425513-A1 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116323583-A | Heterobiaryl compounds and imaging agents for imaging huntingtin | CHDI基金会股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4192819-A1 | HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | disclosed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| CN-102498103-A | Pyrazine carboxamides as DGAT1 inhibitors | ASTRAZENECA AB | 2012-06-13 | — | — | CN | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| CN-1278763-C | Polyimide gas separation membrane | PRAXAIR TECHNOLOGY INC (FR) | 2006-10-11 | — | — | CN | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| CN-1293081-A | Polyimide gas separation membrane | PRAXAIR TECHNOLOGY INC (US) | 2001-05-02 | — | — | CN | disclosed |
| CN-1293080-A | Production of improved polyimide separation membrane and its use | PRAXAIR TECHNOLOGY INC (US) | 2001-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | SIRT3 2658/4885TDP1 4621/4885NNMT 2319/4885 |
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | SIRT3 3271/4885TDP1 1398/4885NNMT 1000/4885 |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | SIRT3 409/4885TDP1 3712/4885NNMT 340/4885 |
| US-20240425513-A1 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | USP28, USP25, USP39 | SIRT3 1033/4885TDP1 2643/4885NNMT 2093/4885 |
| US-20120238549-A1 | Nuclear Hormone Receptor Modulators | NR5A1, NR5A2, NR3C2 | SIRT3 799/4885TDP1 4700/4885NNMT 1490/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | SIRT3 3040/4885TDP1 2102/4885NNMT 4349/4885 |
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | HTT, HYPK, ATXN2L | SIRT3 4347/4885TDP1 1002/4885NNMT 4689/4885 |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ACSL3 | SIRT3 716/4885TDP1 4000/4885NNMT 1039/4885 |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, ADSS2, GLS2 | SIRT3 409/4885TDP1 3712/4885NNMT 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.